Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Aigen Investment Management LP

Aigen Investment Management LP grew its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 35.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,153 shares of the biopharmaceutical company’s stock after acquiring an additional 5,263 shares during the quarter. Aigen Investment Management LP’s holdings in Intra-Cellular Therapies were worth $1,683,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ITCI. Wasatch Advisors LP boosted its stake in Intra-Cellular Therapies by 3.5% in the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock worth $281,601,000 after purchasing an additional 130,351 shares in the last quarter. Bellevue Group AG lifted its stake in shares of Intra-Cellular Therapies by 0.6% during the third quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock worth $181,873,000 after buying an additional 14,342 shares during the period. State Street Corp grew its holdings in shares of Intra-Cellular Therapies by 3.1% during the third quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company’s stock valued at $136,017,000 after buying an additional 56,664 shares during the last quarter. Franklin Resources Inc. raised its stake in Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock worth $129,463,000 after acquiring an additional 155,655 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Intra-Cellular Therapies by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,708,301 shares of the biopharmaceutical company’s stock worth $125,029,000 after acquiring an additional 22,128 shares during the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

NASDAQ:ITCI opened at $131.24 on Wednesday. The stock has a market capitalization of $13.95 billion, a PE ratio of -150.85 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a fifty-two week low of $63.30 and a fifty-two week high of $131.36. The company has a fifty day moving average of $116.44 and a two-hundred day moving average of $92.52.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ITCI shares. Royal Bank of Canada restated a “sector perform” rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Piper Sandler reaffirmed a “neutral” rating and issued a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $140.00 to $132.00 in a report on Monday, February 24th. Finally, Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Ten investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $106.08.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.